Kyowa Kirin International

Company snapshot

At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas

• 2 approved product(s) across US/EU regulatory metadata.
• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kyowa Kirin International. Not investment advice.

• Peer + 0 momentum

  Janssen-Cilag International N.V

  TA overlap score 40

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Kyowa Kirin International.

1. Jun 8, 2026 Clinical update

   2223-001 — Phase 1

2. Jun 8, 2026 Clinical update

   saxagliptin — Phase 2

3. Jun 8, 2026 Clinical update

   POTELIGEO 4 mg/mL concentrate for solution for infusion — Phase 2

4. Jun 8, 2026 Clinical update

   ARQ 197 — Phase 1

5. Jun 5, 2026 Clinical update

   KW-6500 — Phase 3

View all clinical trial activity →

• What is Kyowa Kirin International?

  KYOWA KIRIN AUSTRALIA is a pharma organization headquartered in AU. Primary therapeutic focus areas include Aplastic Anemia, Advanced Hepatocellular Carcinoma, Advanced or Recurrent Breast Cancer, Moderate to Severe Plaque Psoriasis, Alzheimer Disease. NovaPharmaNews links 15 cli

• Is Kyowa Kirin International publicly traded?

  Kyowa Kirin International appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Kyowa Kirin International develop or market?

  We link 12 drug profile(s) where Kyowa Kirin International is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kyowa-kirin-holdings-b-v#company-drugs.

• What are the latest developments for Kyowa Kirin International?

  In the last 12 months our linked public records show 15 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kyowa Kirin International focus on?

  Kyowa Kirin International focuses on Aplastic Anemia, Advanced Hepatocellular Carcinoma, Advanced or Recurrent Breast Cancer based on our analysis of their pipeline programs and drug development activities.